We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The Effects of Crocin on HDL Cholesterol Uptake Capacity in Patients with Metabolic Syndrome: A Randomized Clinical Trial.
- Authors
Saberi-Karimian, Maryam; Mansoori, Amin; Ghazizadeh, Hamideh; Ferns, Gordon A.; Aghasizadeh, Malihe; Ghayour-Mobarhan, Majid
- Abstract
Background: HDL cholesterol uptake capacity (CUC) is reduced in patients with metabolic syndrome (MetS). We have assessed the effect of crocin supplementation on HDL CUC in patients with MetS. Methods: A total of 44 subjects with MetS were randomly allocated to one of two groups: one group consumed placebo and the other group received crocin at a dose of 30 mg (2 tablets of 15 mg per day) for 8 weeks. Serum biochemical factors were determined using an AutoAnalyzer BT3000 (BioTechnica, Italy). The modified CUC method is a cell free, simple, and high-throughput assay that used to evaluate HDL CUC of serum samples. The decision tree analysis was undertaken using JMP Pro (SAS) version 13. Results: The mean age of the crocin and placebo groups were 38.97±13.33 and 43.46±12.77 years, respectively. There was a significant increase in serum HDL CUC in the crocin group comparing with the placebo group in patients with MetS (Pvalue< 0.05). The decision tree analysis showed that subjects with HDL CUC more than 0.89% did not have hypertension (P-value<0.05). Conclusion: Crocin supplementation at a dose of 30 mg for a period of 8 weeks can improve serum HDL CUC in patients with MetS.
- Subjects
CROCIN; HDL cholesterol; METABOLIC syndrome; PATIENTS' attitudes; CLINICAL trials
- Publication
Journal of Nutrition, Fasting & Health, 2022, Vol 10, p147
- ISSN
2821-2746
- Publication type
Article